Shanghai Pharmaceuticals Holding Co Ltd Class H
02607: XHKG (HKG)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
HK$15.60 | Fmgct | Jlsgnscn |
Shanghai Pharmaceuticals' Full-Year Results In Line; Shares Undervalued
Narrow-moat Shanghai Pharmaceuticals, or SPH, announced full-year results that were in line with our expectations. Revenue was CNY 216 billion and CNY 111 billion for the full year and second half, respectively, representing 12.5% and 5.6% year-on-year growth. Profit margins were stable as expected.